Pomalidomide
Top View
- POMALYST Safely Capsules: 1 Mg, 2 Mg, 3 Mg, and 4 Mg (3) and Effectively
- In Silico Analysis of Enantioselective Binding of Immunomodulatory Imide Drugs to Cereblon Takahiro Murai1, Norihito Kawashita1,2, Yu‑Shi Tian3 and Tatsuya Takagi1,2*
- Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Pomalyst® (Pomalidomide) Capsules
- Profile of Pomalidomide and Its Potential in the Treatment of Myelofibrosis
- Pomalyst® (Pomalidomide)
- Annual Rheumatology & Therapeutics Review for Organizations & Societies
- LCA Oral SACT Counselling Handbook
- Celgene Fact Sheet
- Immunomodulation by Durvalumab and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma Mary H
- RUNX Proteins Desensitize Multiple Myeloma to Lenalidomide Via Protecting Ikzfs from Degradation
- Isatuximab with Pomalidomide and Dexamethasone for Treating Relapsed Or Refractory Multiple Myeloma
- Apremilast Is a Selective PDE4 Inhibitor with Regulatory Effects on Innate Immunity, Cellular Signalling (2014), 2 P.H
- Bristol-Myers Squibb Company
- Assessment Report for Otezla
- Pomalidomide for Cgvhd CC Protocol #: 12-C-0197 J NCT #: NCT01688466 Version Date: 9/14/2018
- Use of Pembrolizumab with Or Without Pomalidomide in HIV-Associated Non-Hodgkin's Lymphoma